Genmab — Maj 2018
-
Man bliver tvunget til at erkende, at en aktie der er skortet af så stor en fond ikke kan stige betydeligt selv ikke på gode nyheder. Den stiger men falder hurtigt tilbage igen. Det ses ALTID lige indtil fonden tvinges til at opgive sine shorts eller bliver tilfreds med gevinsten og lukker. I mellemtiden er der så gode trading muligheder men for den langsigtede er det bare at vente tålmodig, hvis man tror på casen.
-
meanwhile Novartis, receives second FDA approval for their CAR-T - https://www.novartis.com/news/media-releases/kymriahr-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma
-
Nogle der har læst denne og vil give en kommentar dertil? Er det noget der truer genmab casen?
https://medwatch.dk/secure/Medicinal___Biotek/article10564531.ece?utm_source=Feed&utm_medium=latest -
Janssen buys an immunotherapy company specialising in oncolytic viruses - https://www.prnewswire.com/news-releases/janssen-to-acquire-benevir-biopharm-to-advance-immunotherapy-regimens-300640969.html - http://benevir.com/
-
The Tisotumab Vedotin (HuMax
-TF-ADC) Safety Study in Patients With Solid Tumors was updated: was completed in December, enrollment 24 against the anticipated 44 - https://clinicaltrials.gov/ct2/history/NCT02552121?A=8&B=9&C=merged -
Hvornår får vi senest afgørelsen for den kommende 1.linje godkendelse? Og hvor meget regner i med det vil påvirke kursen?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind